Type 2 diabetes: one disease, many pathways

被引:36
|
作者
Ha, Joon [1 ]
Sherman, Arthur [1 ]
机构
[1] NIH, Lab Biol Modeling, Bldg 10, Bethesda, MD 20892 USA
关键词
diabetes; glucose; insulin; mathematical modeling; metabolism; BETA-CELL MASS; IMPAIRED GLUCOSE-TOLERANCE; K-ATP CHANNEL; INSULIN-RESISTANCE; MATHEMATICAL-MODEL; AMPLIFYING PATHWAY; FASTING GLUCOSE; SECRETION; PROGRESSION; SENSITIVITY;
D O I
10.1152/ajpendo.00512.2019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is a chronic, progressive disease that calls for longitudinal data and analysis. We introduce a longitudinal mathematical model that is capable of representing the metabolic state of an individual at any point in time during their progression from normal glucose tolerance to type 2 diabetes (T2D) over a period of years. As an application of the model, we account for the diversity of pathways typically followed. focusing on two extreme alternatives, one that goes through impaired fasting glucose (IFG) first and one that goes through impaired glucose tolerance (IGT) first. These two pathways are widely recognized to stem from distinct metabolic abnormalities in hepatic glucose production and peripheral glucose uptake. respectively. We confirm this but go beyond to show that IFG and IGT lie on a continuum ranging from high hepatic insulin resistance and low peripheral insulin resistance to low hepatic resistance and high peripheral resistance. We show that IFG generally incurs IGT and IGT generally incurs IFG on the way to T2D, highlighting the difference between innate and acquired defects and the need to assess patients early to determine their underlying primary impairment and appropriately target therapy. We also consider other mechanisms, showing that IFG can result from impaired insulin secretion, that non-insulindependent glucose uptake can also mediate or interact with these pathways, and that impaired incretin signaling can accelerate T2D progression. We consider whether hyperinsulinemia can cause insulin resistance in addition to being a response to it and suggest that this is a minor effect.
引用
收藏
页码:E410 / E426
页数:17
相关论文
共 50 条
  • [1] The Many Faces of Hepatitis C: Liver Disease and Type 2 Diabetes
    Milner, Kerry-Lee
    Chisholm, Donald
    George, Jacob
    HEPATOLOGY, 2009, 50 (03) : 668 - 670
  • [2] The Many Faces of Type 2 Diabetes
    Flood, Thomas
    POSTGRADUATE MEDICINE, 2010, 122 (04) : 218 - 223
  • [3] Autoimmune diabetes: how many steps for one disease?
    Bach, JF
    Chatenoud, L
    Herbelin, A
    Gombert, JM
    Carnaud, C
    RESEARCH IN IMMUNOLOGY, 1997, 148 (05): : 332 - 338
  • [4] Proteomic pathways to metabolic disease and type 2 diabetes in the pancreatic islet
    Yau, Belinda
    Naghiloo, Sheyda
    Diaz-Vegas, Alexis
    Carr, Austin V.
    Van Gerwen, Julian
    Needham, Elise J.
    Jevon, Dillon
    Chen, Sing-Young
    Hoehn, Kyle L.
    Brandon, Amanda E.
    Macia, Laurence
    Cooney, Gregory J.
    Shortreed, Michael R.
    Smith, Lloyd M.
    Keller, Mark P.
    Thorn, Peter
    Larance, Mark
    James, David E.
    Humphrey, Sean J.
    Kebede, Melkam A.
    ISCIENCE, 2021, 24 (10)
  • [5] One journey, many pathways
    Stanley, F
    INTERNAL MEDICINE JOURNAL, 2003, 33 (1-2) : 59 - 61
  • [6] Type 2 diabetes: one disease, multiple cardiovascular risk factors
    Calles-Escandon, J
    Garcia-Rubi, E
    Mirza, S
    Mortensen, A
    CORONARY ARTERY DISEASE, 1999, 10 (01) : 23 - 30
  • [7] Many (converging) pathways, one destination
    Katrin Legg
    Nature Reviews Molecular Cell Biology, 2011, 12 : 465 - 465
  • [8] Pharmacology of signaling pathways: In type 2 diabetes
    Meerza, Dilnasheen
    Naseem, Imrana
    Ahmed, Jamal
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2013, 7 (03) : 180 - 185
  • [9] Dysregulated pathways in type 2 diabetes mellitus
    Li, H.
    Li, H.
    Ran, J.
    Mao, X.
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (03): : 1426 - 1443
  • [10] Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 Diabetes
    Jones, Allan
    Kulozik, Philipp
    Ostertag, Anke
    Herzig, Stephan
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (04) : 787 - 808